**Core tip:** Previous studies have reported that lymphovascular invasion (LVI) provokes an adverse impact on the long-term survival of several malignances, including breast, gastric, and esophageal carcinoma, among many others. However, the correlation between LVI and hilar cholangiocarcinoma remains unclear. In our study, LVI was found to be an independent risk factor for overall survival and disease-free survival in Bismuth-Corlette type IV hilar cholangiocarcinoma patients. To our knowledge, this report indicates for the first time that LVI is an adverse predictor of long-term survival in the setting of type IV hilar cholangiocarcinoma.

INTRODUCTION
============

Hilar cholangiocarcinoma (HC), also known as Klatskin tumor, is a neoplasia arising from the biliary epithelium at the common hepatic duct bifurcation and may extend to the intrahepatic biliary tree and liver\[[@B1],[@B2]\]. The only clinical approach that is considered to provide patients with an opportunity for a curative outcome and importantly long-term survival is radical surgical resection\[[@B2]-[@B6]\]. The Bismuth-Corlette classification is the most widely used preoperative system of evaluation that can predict resectability of the lesion and assist in the design of an appropriate surgical approach. A Bismuth type IV lesion is defined as a tumor that can invade the secondary biliary radicals of both hepatic ducts. During the past decades, accompanied liver resection has been increasingly but gradually recognized as the mainstay of surgical approaches for targeting a Bismuth type IV tumor\[[@B7]-[@B9]\], however, there are relatively few studies that have reported in any detail the factors that might affect long-term survival of type IV HC patients. The over-arching aim of the current study was to identify prognostic factors for long-term survival of patients following radical surgery for type IV HC patients, especially in the setting of lymphovascular invasion (LVI).

MATERIALS AND METHODS
=====================

Patient selection
-----------------

One hundred and forty-two consecutive patients who underwent radical resection for a pathological diagnosis of type IV HC at the West China Hospital between January 2000 and February 2012 were enrolled in this study and then reviewed retrospectively. The inclusion criteria included the following: (1) patients who were confirmed with Bismuth type IV HC by pathological examination; and (2) patients who had undergone radical resection (R0 and R1 resection). The exclusion criteria included the following: (1) patients with gallbladder or intrahepatic cholangiocarcinoma extending to the hilum; (2) presence of a recurrent or metastatic tumor; and (3) R2 resection.

Preoperative workup
-------------------

Preoperative assessment consisted of acquiring a medical history, physical examination, laboratory tests and radiographic analyses. All patients were evaluated by contrast-enhanced ultrasound, contrast-enhanced computed tomography or magnetic resonance cholangiography with magnetic resonance cholangiopancreatography with the intention of determining the Bismuth type, the location and extent of the tumor. Biliary drainage, including endoscopic retrograde cholangiopancreatography (ENBD) and percutaneous transhepatic cholangiodrainage (PTCD), was applied in the setting of patients presenting with obstructive jaundice that exceeded 85 μmol/L total bilirubin.

Surgical characteristics of the patients
----------------------------------------

Based on the relative location and extent of the tumor, different types of resection were performed, which included extrahepatic bile duct resection and *en bloc* resection of the caudate lobe combined with left hemihepatectomy, right hemihepatectomy and trisectionectomy. In addition, standard regional lymph node dissection should be performed. However, under conditions where tumor metastases to the distant lymph nodes was confirmed during surgery, the surgical intervention was abandoned. According to the American Joint Committee on Cancer (AJCC, 7^th^ edition), the location of regional lymph nodes was defined as follows: along the common bile duct, cystic duct, portal vein and proper hepatic artery\[[@B10]\]. Vascular resection and reconstruction was only performed when vessels could not be detached from the tumor.

Pathological examination
------------------------

The pathological evidence of cancer was determined by examination of paraffin sections. All included Bismuth type IV HC cases were histopathologically confirmed by an experienced pathologist. The presence of tumor emboli within peritumoural endothelial lined spaces was defined as LVI. Resection margin was defined as ductal (*i.e*., proximal and distal ducts) and with evidence of radial margins. The radial margin was defined as the vertical margin between the tumor edge and dissected periductal structures (*e.g*., liver parenchyma, blood vessels and adjacent fat tissues). An R0 resection was defined as the presence of a microscopically tumor-free resection margin. An R1 resection was defined as microscopic evidence of tumor tissue at the resection margin, and an R2 resection was defined as macroscopic evidence of tumor tissue at the resection margin. In this study, radical resection was defined as an R0 and R1 resection, a negative resection margin indicated R0 resection, and a positive resection margin indicated an R1 resection.

Follow-up
---------

Whether or not chemotherapy and radiotherapy can benefit HC patients was controversial. None of the patients received postoperative routine chemotherapy or radiotherapy. All enrolled patients had routine follow-ups every 3 mo in the first year and every 6 mo subsequently until at least 5 years after the surgery. The tumor markers \[serum levels of carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen\], liver functions and ultrasonography were conducted. If there was a suspicion of recurrence, contrast-enhanced computed tomography or magnetic resonance imaging was further performed. Tumor recurrence was diagnosed on the basis of the combined findings of typical radiological appearance, quantification of CA19-9 levels, and clinical presentation. The date of the first suspicious radiological finding was recorded as the date of initial disease recurrence.

Statistical analysis
--------------------

Patient data were retrospectively collected and statistical analyses were performed with SPSS version 19.0 (SPSS Inc. Chicago, IL, United States). Survival was described using the Kaplan-Meier method and differences between subgroups were reviewed by the log-rank test. Multivariate analysis for prognostic factors was performed using a Cox proportional hazards model to analyze variables whose *P*-value was less than 0.1 in the univariate analysis. Multiple logistical regression analysis was performed to determine the association between LVI and potential variables. Two-sided *P* values \< 0.05 were considered statistically significant.

RESULTS
=======

Patients' characteristics and operative outcomes
------------------------------------------------

Patients' characteristics and operative outcomes are shown in Table [1](#T1){ref-type="table"}. Altogether 142 patients had a radical resection for type IV HC, including 75 men and 67 women with a median age of 59 years (range: 23-78). Pre-operative biliary drainage was carried out in 105 of the 123 obstructive jaundice (total bilirubin \> 85 μmol/L) patients, wherein 71 patients underwent PCTD and 34 patients underwent ENBD. Preoperative portal vein embolization was performed in 6 patients.

###### 

Demographics and operative outcomes

  **Characteristic**                                     ***n* (%)**
  ------------------------------------------------------ -----------------
  Age (yr)[1](#T1FN1){ref-type="table-fn"}               59 (23-78)
  Gender                                                 
  Male                                                   75 (52.8)
  Female                                                 67 (47.2)
  Albumin level (g/L)[2](#T1FN2){ref-type="table-fn"}    36.74 ± 4.93
  CA19-9                                                 
  \> 200                                                 82 (57.7)
  \< 200                                                 60 (42.3)
  Radiological examination                               
  Contrast-enhanced US                                   8 (5.6)
  Contrast-enhanced CT                                   43 (30.3)
  MRI + MRCP                                             91 (64.1)
  Operative time (min)[2](#T1FN2){ref-type="table-fn"}   429.47 ± 134.19
  Blood loss (ml)[1](#T1FN1){ref-type="table-fn"}        600 (180-4000)
  Transfusion                                            76 (53.5)
  R0 resection                                           107 (75.4)
  Differentiation degree                                 
  Well differentiated                                    14 (9.9)
  Moderately differentiated                              90 (63.4)
  Poorly differentiated                                  38 (26.8)
  Perineutral invasion positive                          69 (48.6)
  N stage                                                
  N0                                                     89 (62.7)
  N1                                                     53 (37.3)
  Tumor diameter (mm)[1](#T1FN1){ref-type="table-fn"}    30 (12-55
  Hospital stay[1](#T1FN1){ref-type="table-fn"}          19 (5-115)

Parameters are presented as median and range;

Parameters are presented as mean ± SD.

Radical resection included extrahepatic bile duct resection and *en bloc* resection of the caudate lobe combined with left hemihepatectomy (*n* = 73, 51.4%), extended left hemihepatectomy (*n* = 5, 3.5%), left trisectionectomy (*n* = 6, 4.2%), right hemihepatectomy (*n* = 51, 35.9%), extended right hemihepatectomy (*n* = 5, 3.5%), and right trisectionectomy (*n* = 2, 1.4%). Regional lymph node dissection was conventionally performed. The R0 resection rate was 75.6%.

Clinicopathological variables influencing DFS and OS
----------------------------------------------------

As shown in Table [2](#T2){ref-type="table"}, potential factors that might influence the DFS and OS were analyzed. Univariate analysis demonstrated that age (*P* = 0.039), preoperative ALB (*P* = 0.005), resection margin (*P* \< 0.001), histologic grade (*P* = 0.023), T stage (*P* = 0.004), N stage (*P* \< 0.001), AJCC stage (*P* \< 0.001), LVI (*P* \< 0.001), tumor size (*P* \< 0.001), portal vein invasion (*P* = 0.003) and hepatic artery invasion (*P* = 0.008) significantly influenced DFS. By contrast, patient gender, preoperative CA19-9, surgical method, perineural invasion and transfusion did not significantly influence DFS. Preoperative ALB (*P* = 0.009), resection margin (*P* \< 0.001), histologic grade (*P* = 0.026), T stage (*P* = 0.001), N stage (*P* \< 0.001), AJCC stage (*P* \< 0.001), LVI (*P* \< 0.001), tumor size (*P* \< 0.001), portal vein invasion (*P* = 0.002) and hepatic artery invasion (*P* = 0.013), but not patient age, gender, preoperative CA19-9, surgical methods, perineural invasion or transfusion, significantly influenced the OS. Multivariate analysis indicated that positive resection margin, higher N stage, tumor size \> 30 mm and LVI were adverse factors that influenced DFS and OS.

###### 

Potential prognostic factors for disease-free survival and overall survival after radical resection for type IV hilar cholangiocarcinoma patients excluding operative mortality *n* (%)

  **Variable**              **Disease-free survival**   **Overall survival**                                                                                   
  ------------------------- --------------------------- ---------------------- ---------------------- ---------- ----------- ---------- ---------------------- ----------
  Gender                                                0.682                                                                0.965                             
  Male                      13 (18.8)                                                                            14 (20.3)                                     
  Female                    10 (16.4)                                                                            10 (16.4)                                     
  Age (yr)                                              0.039                  1.291 (0.680-2.453)    0.435                  0.230                             
  \< 65                     19 (19.2)                                                                            20 (20.2)                                     
  \> 65                     4 (12.9)                                                                             4 (12.9)                                      
  CA19-9                                                0.287                                                                0.301                             
  \< 200                    13 (23.2)                                                                            14 (25)                                       
  \> 200                    10 (13.5)                                                                            10 (13.5)                                     
  ALB (g/L)                                             0.005                  0.669 (0.413-1.085)    0.103                  0.009      0.760 (0.492-1.173)    0.215
  \< 35                     3 (7.1)                                                                              3 (7.1)                                       
  \> 35                     21 (23.9)                                                                            20 (22.7)                                     
  Surgical method                                       0.847                                                                0.684                             
  Left-sided hepatectomy    13 (15.1)                                                                            13 (15.1)                                     
  Right-sided hepatectomy   10 (17.2)                                                                            11 (19.0)                                     
  Resection margin                                      \< 0.001               6.255 (3.485-11.229)   \< 0.001               \< 0.001   6.776 (3.988-11.479)   \< 0.001
  Positive                  0                                                                                    0                                             
  Negative                  23 (23.7)                                                                            24 (24.7)                                     
  Histologic grade                                      0.023                  1.594 (0.994-2.554)    0.053                  0.026      1.294 (0.830-2.017)    0.256
  Well/moderate             20 (21.5)                                                                            21 (22.6)                                     
  poor                                                                                                           3 (8.1)                                       
  Perineural invasion                                   0.211                                                                0.417                             
  Present                   14 (22.6)                                                                            15 (24.2)                                     
  Absent                    9 (13.2)                                                                             9 (13.2)                                      
  T stage                                               0.004                  1.582 (0.390-6.415)    0.521                  0.001      2.399 (0.734-7.836)    0.147
  T1/2                      22 (22)                                                                              21 (21)                                       
  T3/4                      2 (6.7)                                                                              2 (6.7)                                       
  N stage                                               \< 0.001               2.902 (1.132-7.439)    0.027                  \< 0.001   2.827 (1.243-6.429)    0.013
  N0                        22 (27.2)                                                                            23 (28.4)                                     
  N1                        1 (2.0)                                                                              1 (2.0)                                       
  AJCC stage                                            \< 0.001               0.673 (0.289-1.567)    0.358                  \< 0.001   0.844 (0.351-2.028)    0.704
  Stage I/II                20 (32.8)                                                                            21 (34.4)                                     
  Stage III/IV              3 (4.9)                                                                              3 (4.9)                                       
  Lymphovascular invasion                               \< 0.001               2.799 (1.588-4.935)    \< 0.001               \< 0.001   2.908 (1.712-4.938)    \< 0.001
  Present                   0                                                                                                0.000                             
  Absent                    23 (22.8)                                                                            24 (24.8)                                     
  Tumor size (mm)                                       \< 0.001               1.942 (1.176-3.209)    0.010                  \< 0.001   1.739 (1.101-2.745)    0.018
  ≤ 30                      15 (20)                                                                              16 (21.3)                                     
  \> 30                     8 (14.5)                                                                             8 (14.5)                                      
  Portal vein invasion                                  0.003                  1.759 (0.534-5.800)    0.353                  0.002      1.130 (0.408-3.127)    0.815
  Present                   1 (4.2)                                                                              1 (4.2)                                       
  Absent                    22 (20.8)                                                                            23 (21.7)                                     
  Hepatic invasion                                      0.008                  1.499 (0.612-3.668)    0.376                  0.013      1.196 (0.526-2.719)    0.669
  Present                   1 (9.1)                     1 (9.1)                                                  1 (9.1)                                       
  Absent                    22 (18.5)                   22 (18.5)                                                23 (19.3)                                     
  Transfusion                                           0.445                                                                0.199                             
  Yes                       11 (16.4)                                                                            11 (16.4)                                     
  No                        12 (19.0)                                                                            13 (20.6)                                     

Association between LVI and N stage and tumor size
--------------------------------------------------

LVI was confirmed histologically in 29 (20.4%) of the 142 patients. Table [3](#T3){ref-type="table"} shows the association of LVI with tumor size, N stage and AJCC stage. On univariate analysis, N stage (*P* \< 0.001) and tumor size (*P* = 0.001), but not AJCC stage, were significantly associated with LVI. Multivariate analysis using a logistic regression model indicated that N1 stage (*P* = 0.026) and tumor size \> 30 mm were significant factors that were associated with LVI in Bismuth type IV HC. DFS and OS based on LVI status are shown in Figure [1](#F1){ref-type="fig"}. The 5-year DFS rate in the LVI negative group was significantly higher than that in the LVI positive group (22.8% *vs* 0%, *P* \< 0.001) as was the OS (23.8% *vs* 0%, *P* \< 0.001). Based on the LVI status, N0 stage patients and patients with tumor size ≤ 30 mm were divided into two subgroups, respectively. In the N0 stage subgroups, the 5-year DFS rate in the LVI negative group was significantly higher than that in the LVI positive group (31.0% *vs* 0%, *P* = 0.002), and the 5-year OS rate in the LVI negative group was also significantly higher than that in the LVI positive group (32.4% *vs* 0%, *P* = 0.001). In the tumor size ≤ 30 mm subgroups, the 5-year DFS rate in the LVI negative group was significantly higher than that in the LVI positive group (31.8% *vs* 0%, *P* = 0.003), and the 5-year OS rate in the LVI negative group was significantly higher than that in the LVI positive group (34.3% *vs* 0%, *P* = 0.006).

![Disease-free survival and overall survival based on lymphovascular invasion in type IV hilar cholangiocarcinoma patients with radical resection. A: The 5-yr DFS rate in the LVI negative group was significantly higher than that in the LVI positive group; B: The 5-yr OS rate in the negative group was significantly higher than that in the LVI positive group. LVI: Lymphovascular invasion; DFS: Disease-free survival; OS: Overall survival.](WJG-23-6685-g001){#F1}

###### 

Logistic regression analysis for factors associated with lymphovascular invasion

  **Variable**          **Lymphovascualr invasion (+), *n* = 29**   **Lymphovascualr invasion (-), *n* = 113**   **Univariate analysis (*P* value)**   **OR (95%CI)**        **Multivariate analysis (*P* value)**
  --------------------- ------------------------------------------- -------------------------------------------- ------------------------------------- --------------------- ---------------------------------------
  AJCC stage                                                                                                     0.063                                 0.223 (0.026-1.927)   0.173
  I/II                  8                                           27                                                                                                       
  III/IV                21                                          86                                                                                                       
  Tumor diameter (mm)                                                                                            0.001                                 3.258 (1.288-8.236)   0.013
  ≤ 30                  10                                          77                                                                                                       
  \> 30                 19                                          36                                                                                                       
  N stage                                                                                                        \< 0.001                              3.312 (1.338-8.198)   0.026
  N0                    10                                          79                                                                                                       
  N1                    19                                          34                                                                                                       

DISCUSSION
==========

LVI is recognized as a dismal prognostic factor for OS in patients with breast cancer, colorectal cancer, and esophageal cancer\[[@B11]-[@B14]\]. However, no studies have yet been published on whether LVI affects the prognosis of Bismuth type IV HC. Thus, the current study was undertaken to clarify the significance of LVI in type IV HC patients who had a radical resection. LVI is defined as the involvement of arterial vessels, venules and lymphatic channels\[[@B11]\], but it is histologically difficult to distinguish, and the American Joint Committee on Cancer/Union Internationale Contre Cancer staging guidelines use the term lymphovascular to refer to those structures\[[@B11]\]. Furthermore, LVI can be confirmed specifically on HE-stained specimens\[[@B13]\]. In our series, LVI was confirmed histopathologically in 29 patients.

It is well recognized that resection margin status is the most important factor affecting long-term survival outcomes of HC patients\[[@B14],[@B15]\], and positive resection margin remains a major dismal prognostic factor for type IV HC patients. Furthermore, since type IV HC had been considered unresectable\[[@B16]\], radical resection performed in such patients is technically challenging. Bracingly, in our center the R0 resection rate is 75.4%. Regional lymph node involvement represents another important dismal prognostic factor in HC patients who had undergone radical resection\[[@B17],[@B18]\]. Concordantly, the multivariate analysis showed that lymph node metastasis was an adverse factor affecting DFS and OS in type IV HC. Furthermore, DeOliveira et al\[[@B19]\] proposed a new staging system, in which tumor size \> 30 mm was defined as the T3 stage. The choice of 30 mm as a cutoff value for T3 is based on increasing evidence that the smaller the tumor, the better the prognosis\[[@B20],[@B21]\]. Our results indicated that tumor size \> 30 mm had an unfavorable impact on both DFS and OS. More importantly, we found that LVI is a significant adverse prognostic factor influencing DFS and OS in multivariate analysis. To our knowledge, no other reports have shown the correlation between LVI and the prognosis of type IV HC.

Previous studies suggested that LVI may interact with other adverse risk factors, which then have a dismal impact on the OS of esophageal cancer patients\[[@B22],[@B23]\]. Lee et al\[[@B24]\] found that the presence of LVI correlated with the presence of lymph node metastasis in patients with gastric carcinoma. For different types of cholangiocarcinoma, the effect of LVI on prognosis was also different. Kim et al\[[@B25]\] reported that LVI did not influence the survival of patients with distal cholangiocarcinoma. Fisher et al\[[@B26]\] reported that LVI had an adverse influence on survival of patients with intrahepatic cholangiocarcinoma. Both of studies found that LVI was associated with lymph node metastasis\[[@B25],[@B26]\]. In our analysis, N1 stage was a significant factor that was associated with LVI in type IV HC patients. It is generally known that tumor cells and tumor stromal cells (such as macrophages and thrombocytes) can produce pro-lymphangiogenic factors, which increase lymphovascular density in and around the tumors\[[@B27],[@B28]\], mainly peritumoral regions. Lymph node metastases often occurred in tumors lacking intratumoral functional lymphatics, suggesting that functional lymphatics at the peritumoral regions are the route of lymphatic dissemination. Increased peritumoral lymphovascular density is considered to increase the flow of lymphatic fluid and provide an opportunity for invasive tumor cells to access the lymphatic vessels\[[@B29]\]. This may elucidate our results that LVI is closely related to lymph node metastasis. Moreover, we speculated that LVI may be the precursor of lymph node metastasis. Thus, we divided patients without lymph nodes metastases into LVI positive and LVI negative subgroups, and found that the 5-year DFS and OS rates in the LVI negative group were significantly higher than those in the LVI positive group (Figure [2A](#F2){ref-type="fig"} and B). This result indicates that LVI is an admirable prognostic predictor for patients with type IV HC when lymph node metastasis is absent.

![Disease-free survival and overall survival based on lymphovascular invasion in type IV hilar cholangiocarcinoma patients without lymph node metastasis. A: The 5-yr DFS rate in the LVI negative group was significantly higher than that in the LVI positive group; B: The 5-yr OS rate in the negative group was significantly higher than that in the LVI positive group. LVI: Lymphovascular invasion; DFS: Disease-free survival; OS: Overall survival.](WJG-23-6685-g002){#F2}

Additionally, tumor size \> 30 mm was another significant factor correlated with LVI in our series. Tumor size is recognized as a staging basis for many malignant tumors, including thyroid carcinoma, breast carcinoma, and liver carcinoma among others. Gurleyik et al\[[@B30]\] reported that LVI correlated with tumor size, and the rate of LVI positive increased with tumor size in patients with breast carcinoma. The significant correlation between LVI and tumor size could be explained through two potential aspects: (1) as the tumor size increases, the peritumoral areas increase. Thus, the tumor is endowed with the potential to make contact with an increasing lymphovasculature, and thus the possibility of LVI increases; and (2) tumor size is proportional to the time of growth: the larger the tumor, the greater the duration of time that the tumor can continue developing and growing in size. During a relatively longer growth time, a tumor has increasing opportunities to develop LVI. In our study, patients with tumor size ≤ 30 mm were also divided into LVI positive and LVI negative subgroups. Here, the 5-year DFS and OS rates in the LVI negative group were significantly higher than those found in the LVI positive group (Figure [3A](#F3){ref-type="fig"} and B). This result indicates that LVI is also an excellent prognostic predictor in type IV HC patients with smaller tumor size.

![Disease-free survival and overall survival based on lymphovascular invasion in type IV hilar cholangiocarcinoma patients with tumor size ≤ 30 mm. A: The 5-yr DFS rate in the LVI negative group was significantly higher than that in the LVI positive group; B: The 5-yr OS rate in the negative group was significantly higher than that in the LVI positive group. LVI: Lymphovascular invasion; DFS: Disease-free survival; OS: Overall survival.](WJG-23-6685-g003){#F3}

Some limitations of the study should also be taken into account when interpreting the results. First, our study was retrospective with inherent limitations in its design. Thus, some clinical bias was inevitable. Next, LVI was confirmed by hematoxylin and eosin (HE) staining alone without application of an immunohistochemical staining with D2-40 antibody, which may improve the detection rate of LVI\[[@B31]\]. Third, N1 stage and tumor size \> 30 mm might serve as potential confounding factors that could affect the association between LVI and the eventual prognosis. Finally, we did not carry out preclinical medical experiments to elaborate the specific molecular mechanism that could play a key role in the capacity of LVI to affect the prognosis of type IV HC patients. Future research should take into account this topic with a greater sample size. Prospective studies, even randomized controlled trials, are also urgently needed. Of course, the specific molecular mechanism responsible for LVI affecting the prognosis of type IV HC patients will be determined by empirical research.

In conclusion, the presence of LVI may be regarded as an indicator of biologically aggressive behavior, metastatic ability, and regional and systemic risk of metastasizing the primary malignancy. LVI is associated with N1 stage and tumor size \> 30 mm and imparts an adverse influence on OS and DFS in type IV HC patients who received radical resection.
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